Milestone Pharmaceuticals Inc. Annual Report - How They Did This Year

Let's chat about Milestone Pharmaceuticals' past year. This summary will help you decide if this company fits your investment goals. We'll cover the important details without confusing financial terms.

Here are some fresh insights from their annual report for the fiscal year ending December 31, 2025.

Who is Milestone Pharmaceuticals?

Milestone Pharmaceuticals is a company based in Québec, Canada. You can find their stock on the Nasdaq Stock Market under MIST. They are a "smaller reporting company" and a "non-accelerated filer." This means they are not yet a giant, well-established company.

For investors, this classification shows Milestone has a public float of less than $75 million. A public float is the value of their publicly traded shares. Their total annual revenues are also less than $100 million. These limits allow them to follow less strict reporting rules than larger companies. This often means the company is still developing, with a focused drug pipeline.

What's Their Main Focus?

Milestone is a pharmaceutical company. This means they develop new medicines. Their main focus is on etripamil, a drug they are developing as a nasal spray.

• CARDAMYST™ (etripamil) for PSVT: Their main goal is to get CARDAMYST™ approved and available. It treats sudden, fast heartbeats in adults, called Paroxysmal Supraventricular Tachycardia (PSVT). The U.S. FDA approved it in late 2024. This was a big step. CARDAMYST™ is the first and only self-administered PSVT therapy. The company now focuses on launching it and building sales. They aim to reach the estimated 2 million PSVT patients in the U.S.
• Etripamil for Atrial Fibrillation: They are also in advanced clinical trials for etripamil. These Phase 3 trials are usually the last step before seeking approval. This use treats another heart rhythm problem, atrial fibrillation (AFib). This could be a larger market than PSVT, affecting millions globally. The ongoing Phase 3 RAPID study checks how well etripamil works and if it's safe for AFib patients. Results are expected in late 2026 or early 2027.
• International Partnerships: They teamed up with Corxel Pharmaceuticals to expand their reach. This 2023 partnership aims to bring etripamil to patients in China, Hong Kong, Macau, and Taiwan. Corxel has the sole right to develop and sell etripamil there. Milestone receives upfront payments. They could also get up to $100 million in development and sales-based payments. Plus, they earn a percentage of net sales. This deal brings in money without issuing more shares. It also uses Corxel's local knowledge.

Financial Snapshot (as of late 2025/early 2026):

• Company Value: As of June 30, 2025, the stock market valued the company at about $98.9 million. This is its market capitalization, or the total value of all its shares.
• Shares Out There: As of March 20, 2026, about 117.7 million shares of Milestone Pharmaceuticals stock were available for trading.
• Money In and Out: Milestone is a clinical-stage company with a new product. They focus on research, development (R&D), and initial sales. They are not yet earning much from CARDAMYST™. This means they are likely losing money, as sales don't cover their high operating costs. Their plan is to raise more money and form partnerships. This funding will support ongoing clinical trials and sales growth.

What Are They Looking Forward To (and What Could Go Wrong)?

Like any drug development company, Milestone's future depends on many events. They are focused on:

• Getting Drugs Approved: Future success largely depends on getting drugs approved. This includes etripamil, by health authorities like the U.S. FDA. Drug development is long, costly, and risky. Many promising drugs fail clinical trials or regulatory checks. They also need approval for new uses of existing drugs, like etripamil for AFib.
• Market Acceptance: Even with approval, people and doctors must use their drugs. They consider how many patients will benefit. They also think about how quickly the market will adopt their treatments. Factors include how well the drug works and its safety. Convenience, like a nasal spray, also matters. Doctor awareness and patient education are key. Selling the drug successfully needs big investments in sales and marketing. It also needs ways to get the drug to patients.
• Money Matters: They constantly review their spending and expected earnings. They also assess their need for more funding. Developing drugs is very expensive. R&D costs often reach hundreds of millions over many years. Milestone is not yet earning much from product sales. They are spending money faster than they earn it. They will likely need to raise more money. This could be by selling more shares. Selling more shares means more shares issued, reducing your ownership percentage. They might also borrow money or form more partnerships. This funds their operations, trials, and drug launches.
• Protecting Their Ideas: Their intellectual property, like drug patents, is very important. They must protect these ideas and may face legal disputes. Patents give them the sole right to sell their drug for a period. This is typically 20 years from filing. This helps them get back money spent on development. However, legal fights over patents or patent expiration could hurt their market exclusivity. This means they might not be the only one who can sell it. It could also hurt their ability to make a profit.
• Insurance Coverage: For widespread use, insurers and government health programs must pay for their drugs. Getting good payment rates and being listed by insurers is vital. This helps patients access the drug and ensures sales success. Without enough coverage, patients might not afford the drug. This would limit how many people use it.
• Competition: The pharmaceutical industry is very competitive. They face other companies developing similar or better treatments. CARDAMYST™ is a new self-administered option for PSVT. But it competes with existing treatments given in healthcare settings. The AFib market is even more crowded. It has many different drug and procedure treatments. New competitors or better treatments could reduce Milestone's portion of sales. It could also limit their ability to set prices.
• Rules and Regulations: Changes in government laws or trade policies could affect their business. This includes changes in drug pricing policies, like the Inflation Reduction Act. Stricter rules for getting drugs approved could also impact them. Healthcare reform or new data privacy laws are other examples. All these could increase their running costs or limit chances to sell.